BACKGROUND: We present survival outcomes of patients registered in the Dutch population-based Eindhoven Cancer Registry (ECR). PATIENTS AND METHODS: Data on patients diagnosed with a melanoma between 1980 and 2002 were obtained from the ECR. Data on vital status up to 1 January 2005 were obtained, up-to-date survival rates were calculated using period analysis. Multivariate analyses were carried out using Cox proportional hazards model. RESULTS: Ten-year crude survival rates were 82% for women and 60% for men (P < 0.05). Thin melanomas (Breslow thickness <or= 2.0 mm) had 5-year crude survival rates >74%, for melanomas >4.0 mm these rates were <65% (P < 0.05). In the early 1980s, 5-year relative survival rates were 84% and 62% for young (<60 years) women and men, and 66% and 69%, respectively, for the elderly (aged 60+). In the period 2000-2002, these rates had improved to >90% for females and to >72% for males. Multivariate analyses showed increased hazard ratios with increasing age and Breslow thickness, being male, having a melanoma on the trunk or unknown sites and having a nodular melanoma. CONCLUSIONS: Despite the absence of improvements in treatment options for melanoma, survival improved significantly, except for elderly males.
BACKGROUND: We present survival outcomes of patients registered in the Dutch population-based Eindhoven Cancer Registry (ECR). PATIENTS AND METHODS: Data on patients diagnosed with a melanoma between 1980 and 2002 were obtained from the ECR. Data on vital status up to 1 January 2005 were obtained, up-to-date survival rates were calculated using period analysis. Multivariate analyses were carried out using Cox proportional hazards model. RESULTS: Ten-year crude survival rates were 82% for women and 60% for men (P < 0.05). Thin melanomas (Breslow thickness <or= 2.0 mm) had 5-year crude survival rates >74%, for melanomas >4.0 mm these rates were <65% (P < 0.05). In the early 1980s, 5-year relative survival rates were 84% and 62% for young (<60 years) women and men, and 66% and 69%, respectively, for the elderly (aged 60+). In the period 2000-2002, these rates had improved to >90% for females and to >72% for males. Multivariate analyses showed increased hazard ratios with increasing age and Breslow thickness, being male, having a melanoma on the trunk or unknown sites and having a nodular melanoma. CONCLUSIONS: Despite the absence of improvements in treatment options for melanoma, survival improved significantly, except for elderly males.
Authors: Jasper I van der Rhee; Femke A de Snoo; Hans F A Vasen; Wolter J Mooi; Hein Putter; Nelleke A Gruis; Nicole A Kukutsch; Wilma Bergman Journal: J Am Acad Dermatol Date: 2011-05-12 Impact factor: 11.527
Authors: Karyn Schmidt; Cailin E Joyce; Frank Buquicchio; Adam Brown; Justin Ritz; Robert J Distel; Charles H Yoon; Carl D Novina Journal: Cell Rep Date: 2016-05-19 Impact factor: 9.423
Authors: Karyn Schmidt; Johanna S Carroll; Elaine Yee; Dolly D Thomas; Leon Wert-Lamas; Steven C Neier; Gloria Sheynkman; Justin Ritz; Carl D Novina Journal: Cell Rep Date: 2019-05-21 Impact factor: 9.423
Authors: Elisabeth Livingstone; Loes M Hollestein; Myrthe P P van Herk-Sukel; Lonneke van de Poll-Franse; Arjen Joosse; Bastian Schilling; Tamar Nijsten; Dirk Schadendorf; Esther de Vries Journal: Cancer Med Date: 2014-06-17 Impact factor: 4.452
Authors: Patricia Markham Risica; Natalie H Matthews; Laura Dionne; Jennifer Mello; Laura K Ferris; Melissa Saul; Alan C Geller; Francis Solano; John M Kirkwood; Martin A Weinstock Journal: Prev Med Rep Date: 2018-04-17